Clinical trial · Observational
Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors
NCT00664131CI-TRIAL-00005532completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment of acute lymphoblastic leukemia achieves high cure rate, but is potentially neurotoxic. Long-term neurologic morbidity in survivors and its effect on function are inadequately studied. Neurologic outcomes will be assessed through an investigator administered questionnaire followed by comprehensive neurologic examination by the study neurologist.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neurological Examination/Questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 1
- interventionNames
- Other: Neurological Examination/Questionnaires
Primary outcomes (2)
- measure
- To estimate prevalence of neurologic symptoms as reported by the patient or parent in childhood acute lymphoblastic leukemia survivors.
- timeFrame
- At lease 5 years from diagnosis and at least one year after completion of therapy.
- measure
- To estimate prevalence of neurologic signs as determined by detailed neurologic examination of childhood acute lymphoblastic leukemia survivors.
- timeFrame
- At lease 5 years from diagnosis and at least one year after completion of therapy.
Secondary outcomes (3)
- measure
- To estimate prevalence of neurologic disability as determined by neurologic symptoms, signs and administered questionnaire instruments.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 28 Years
Show eligibility criteria text
Inclusion Criteria: * Childhood ALL survivors treated on institutional protocols at * Patient will be at least 5-years from ALL diagnosis. * Patient will be at least one year from completion of cancer therapy. * Absence of recurrent or secondary cancer for at least one year day of enrollment. * Between 6-28 years of age at the time of evaluation. * Patient's or at least one parent's English is proficient enough Questionnaire. * Parent and the child agree to participate. Consent only from will suffice if \> 18 years of age at the time of assessment. Exclusion Criteria: * Recurrent tumor or development of secondary cancer * Child or parent refuses to participate * Co-morbid pre-existing disabling neurologic disease, which in the judgment of the principal investigator may compromise clinical observations.
References
Publications (0)
Data not yet available
No reference posted for this study.